Mandate

Vinge advises CELLINK in connection with listing on Nasdaq First North

October 07, 2016

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq First North.

The information memorandum was published on 7 October 2016 and the estimated first day of trading is 3 November 2016. The subscription price in the offer is SEK 26 per share, which corresponds to a pre-money value for CELLINK of approximately MSEK 156. No shares or other securities are being sold by existing shareholders in connection with the offer.

CELLINK develops and sells bioink and bioprinters. Bioink can be combined with conductive cells in order to print functional living tissue and, if future research is successful, complete human organs. CELLINK was founded in 2016 and has won several awards, both scientific and business related, for successful entrepreneurship.

 Vinge’s team consisted of responsible partner Anders Strid together with Frida Bäckegren (capital markets), Jonas Lindblad (employment), Joel Zetterström and Natalie Bäck (IT), Karin Wisenius (competition), Victor Ericsson (tax) and corporate assistant Camilla Andersson.    

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025